Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Br J Haematol. 2018 Apr 19;181(5):642–652. doi: 10.1111/bjh.15251

Figure 3.

Figure 3

In vitro response to ponatinib in BCR/ABL1-like and non-BCR/ABL1-like primary cells; BCR/ABL1+ cells were used as control. A) Average values of 3H-thymidine incorporation of 16 primary B-ALL cells samples after 72 h of treatment with ponatinib (0.01 μM); B) Average values of Annexin V positive primary B-ALL cells samples after 72 h of treatment with ponatinib (0.01 μM). Samples are grouped according to BCR/ABL1-like (n=7), BCR/ABL1-positive (n=4) and non-BCR/ABL1-like (n=6).